PL2142174T3 - Stabilne wodne preparaty G-CSF - Google Patents

Stabilne wodne preparaty G-CSF

Info

Publication number: PL2142174T3
Authority: PL; Poland
Prior art keywords: stable aqueous; csf formulations; formulations; csf; lyophilisates
Prior art date: 2007-04-05

Application number

PL08735029T

Other languages

English (en)

Inventor

Sabine Fürtinger

Heinrich Matous

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-05

Filing date

2008-04-04

Publication date

2011-08-31

2008-04-04 Application filed by Sandoz Ag filed Critical Sandoz Ag

2011-08-31 Publication of PL2142174T3 publication Critical patent/PL2142174T3/pl

Links

238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
239000000843 powder Substances 0.000 abstract 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL08735029T 2007-04-05 2008-04-04 Stabilne wodne preparaty G-CSF PL2142174T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07007221		2007-04-05
EP08735029A EP2142174B1 (en)	2007-04-05	2008-04-04	Stable aqueous g-csf formulations
PCT/EP2008/002700 WO2008122415A1 (en)	2007-04-05	2008-04-04	Stable aqueous g-csf formulations

Publications (1)

Publication Number	Publication Date
PL2142174T3 true PL2142174T3 (pl)	2011-08-31

Family

ID=39512671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08735029T PL2142174T3 (pl)	2007-04-05	2008-04-04	Stabilne wodne preparaty G-CSF

Country Status (11)

Country	Link
US (1)	US9119789B2 (pl)
EP (1)	EP2142174B1 (pl)
JP (1)	JP5349452B2 (pl)
CN (1)	CN101657187B (pl)
AT (1)	ATE493117T1 (pl)
AU (1)	AU2008235044B2 (pl)
CA (1)	CA2679551C (pl)
DE (1)	DE602008004235D1 (pl)
PL (1)	PL2142174T3 (pl)
SI (1)	SI2142174T1 (pl)
WO (1)	WO2008122415A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2399572A1 (en) *	2010-06-22	2011-12-28	Sandoz AG	Long-term storage of non-glycosylated recombinant human G-CSF
AR083006A1 (es)	2010-09-23	2013-01-23	Lilly Co Eli	Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
HK1208231A1 (en)	2012-09-20	2016-02-26	Morphosys Ag	Treatment for rheumatoid arthritis
CN104906053B (zh) *	2015-06-12	2018-01-16	北京四环生物制药有限公司	注射用重组人粒细胞刺激因子冻干粉针剂
CN107921096A (zh)	2015-07-30	2018-04-17	恩多技术公司	用于胰腺癌或结肠癌治疗的集落刺激因子
WO2020002650A1 (en) *	2018-06-29	2020-01-02	Targovax Asa	A formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4126984A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
DE4242863A1 (de) *	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
JP2007204498A (ja)	1999-03-01	2007-08-16	Chugai Pharmaceut Co Ltd	長期安定化製剤
KR20030027077A (ko) *	2000-09-01	2003-04-03	쥬가이 세이야쿠 가부시키가이샤	장기 안정화 용액 제제
GB0031603D0 (en) *	2000-12-23	2001-02-07	Pilkington Plc	Automotive glazing
DE10348550A1 (de) *	2003-10-20	2005-06-16	Hexal Biotech Forschungsgmbh	Stabile wässrige G-CSF-haltige Zusammensetzungen
EP1682184B1 (en) *	2003-11-04	2013-10-16	LEK Pharmaceuticals d.d.	Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
GB0700523D0 (en) *	2007-01-11	2007-02-21	Insense Ltd	The Stabilisation Of Proteins

2008
- 2008-04-04 JP JP2010501436A patent/JP5349452B2/ja not_active Expired - Fee Related
- 2008-04-04 WO PCT/EP2008/002700 patent/WO2008122415A1/en not_active Ceased
- 2008-04-04 AT AT08735029T patent/ATE493117T1/de active
- 2008-04-04 CN CN2008800109149A patent/CN101657187B/zh not_active Expired - Fee Related
- 2008-04-04 AU AU2008235044A patent/AU2008235044B2/en not_active Ceased
- 2008-04-04 US US12/530,671 patent/US9119789B2/en not_active Expired - Fee Related
- 2008-04-04 CA CA2679551A patent/CA2679551C/en not_active Expired - Fee Related
- 2008-04-04 DE DE602008004235T patent/DE602008004235D1/de active Active
- 2008-04-04 EP EP08735029A patent/EP2142174B1/en active Active
- 2008-04-04 PL PL08735029T patent/PL2142174T3/pl unknown
- 2008-04-04 SI SI200830181T patent/SI2142174T1/sl unknown

Also Published As

Publication number	Publication date
HK1135329A1 (en)	2010-06-04
ATE493117T1 (de)	2011-01-15
US20100104627A1 (en)	2010-04-29
AU2008235044B2 (en)	2011-08-25
JP5349452B2 (ja)	2013-11-20
CA2679551A1 (en)	2008-10-16
US9119789B2 (en)	2015-09-01
SI2142174T1 (sl)	2011-04-29
AU2008235044A1 (en)	2008-10-16
WO2008122415A1 (en)	2008-10-16
EP2142174A1 (en)	2010-01-13
JP2010523510A (ja)	2010-07-15
CN101657187A (zh)	2010-02-24
EP2142174B1 (en)	2010-12-29
CA2679551C (en)	2014-10-21
DE602008004235D1 (de)	2011-02-10
CN101657187B (zh)	2012-07-18

Publication	Publication Date	Title
UA94833C2 (en)	2011-06-10	Substituted bicyclolactams
TW200800968A (en)	2008-01-01	Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
UA96449C2 (en)	2011-11-10	Stable laquinimod preparations
MY161415A (en)	2017-04-14	A homeopathic formulation
MY148634A (en)	2013-05-15	Pyridazinone derivatives
PH12013502192A1 (en)	2015-10-12	Antibodies against human angiopoietin 2
PH12014502880A1 (en)	2016-01-18	Lyophilized therapeutic peptibody formulations
SI1818057T1 (sl)	2010-08-31	Stabilne farmacevtske formulacije montelukast natrija
MX2010004576A (es)	2010-05-17	Derivados de pirimidina novedosos.
MX2012007375A (es)	2012-07-30	3-ceto-n-propargil 1-aminoindano.
MX2007008790A (es)	2007-09-11	Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
IL193725A0 (en)	2009-05-04	Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
TW200621313A (en)	2006-07-01	Pharmaceutical compositions
EP2129672A4 (en)	2009-12-09	ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
SI2142174T1 (sl)	2011-04-29	Stabilne vodne G-CSF formulacije
TN2012000105A1 (en)	2013-09-19	Spirolactam derivatives and uses of same
WO2012075015A3 (en)	2012-08-23	Oral metronidazole pharmaceutical compositions
TW200716605A (en)	2007-05-01	2,6-quinolinyl derivatives, processes for preparing them and their uses
MX2008002492A (es)	2008-04-03	Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
WO2006096518A3 (en)	2007-03-22	Improved gacyclidine formulations
TW200738283A (en)	2007-10-16	Formulations of conjugated estrogens and bazedoxifene
MX2009012370A (es)	2010-04-22	Formulacion de antraciclina de baja viscosidad.
TW200616977A (en)	2006-06-01	Enantiomers of selected fused heterocyclics and uses thereof
EP1991248A4 (en)	2009-08-05	ANTIDEPRESSANT PRODRUGS
PL1677818T3 (pl)	2012-07-31	Stabilne kompozycje wodne zawierające G-CSF